WO2004083165A1 - Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden - Google Patents

Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden Download PDF

Info

Publication number
WO2004083165A1
WO2004083165A1 PCT/EP2004/002311 EP2004002311W WO2004083165A1 WO 2004083165 A1 WO2004083165 A1 WO 2004083165A1 EP 2004002311 W EP2004002311 W EP 2004002311W WO 2004083165 A1 WO2004083165 A1 WO 2004083165A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
phenyl
formula
moles
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2004/002311
Other languages
German (de)
English (en)
French (fr)
Inventor
Jochen Hachtel
Bernd Neises
Wilfried Schwab
Roland Utz
Martin Zahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2519209A priority Critical patent/CA2519209C/en
Priority to JP2006504568A priority patent/JP4546952B2/ja
Priority to PL04718192T priority patent/PL1606246T3/pl
Priority to EP04718192A priority patent/EP1606246B1/de
Priority to DE502004011176T priority patent/DE502004011176D1/de
Priority to HK06106890.2A priority patent/HK1086818B/xx
Priority to DK04718192.0T priority patent/DK1606246T3/da
Priority to AU2004222139A priority patent/AU2004222139B2/en
Priority to SI200431463T priority patent/SI1606246T1/sl
Priority to KR1020057017413A priority patent/KR101072237B1/ko
Application filed by Sanofi Aventis Deutschland GmbH, Aventis Pharma Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to MXPA05009764A priority patent/MXPA05009764A/es
Priority to AT04718192T priority patent/ATE468323T1/de
Publication of WO2004083165A1 publication Critical patent/WO2004083165A1/de
Priority to IL170934A priority patent/IL170934A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/30Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00Preparation of carboxylic acid nitriles
    • C07C253/32Separation; Purification; Stabilisation; Use of additives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/26Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups, amino groups and singly-bound oxygen atoms bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/27Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups, amino groups and doubly-bound oxygen atoms bound to the carbon skeleton

Definitions

  • the invention relates to a process for the preparation of 2-cyano-3-hydroxy-N- (phenyl) but-2-enamides from 2-cyano-N- (phenyl) acetamide, in particular the preparation of 2-cyano-3-hydroxy N - [(4-trifluoromethyl) -phenyl] but-2-enamide from 2-cyano-N- (4-trifluoromethyl-phenyl) -acetamide.
  • 2-cyano-3-hydroxy-N- [phenyl] but-2-enamides can be prepared from 2-cyano-N- (phenyl) acetamide in the presence of acetic anhydride and sodium hydroxide.
  • the invention therefore relates to a process for obtaining the compound of the formula I.
  • R1 is a) -CF3, b) -0-CF 3, c) -S-CF 3, d) -OH, e) -N0 2 f) halo, g) benzyl, h) phenyl, i) -O-phenyl, k) -CN,
  • R 2 represents a) - (C 1 -C 4 ) -alkyl, b) halogen or c) represents a hydrogen atom,
  • R1 and R2 are as defined above, in the presence of at least one base, reacting acetic anhydride and at least one solvent and then isolating the compound of formula I formed.
  • the invention further relates to a process for obtaining the compound of formula III
  • the procedure is such that initially the compound of the formula II or (2-cyano-N- (4-trifluoromethyl-phenyl) -acetamide) is introduced into a solvent and the resulting solution or suspension is cooled , Thereafter, the addition of aqueous sodium hydroxide and acetic anhydride and the resulting reaction mixture is stirred or shaken with cooling.
  • the compound of formula I is precipitated with an acid.
  • the isolation of the compound of formula I is carried out for example by crystallization or extraction, for example with ethyl acetate or toluene.
  • the crystallization is promoted by cooling the suspension or further evaporating the solvents.
  • solvent are, for example, water, organic solvents, for example: ketonic solvents such as acetone, methyl ethyl ketone or methyl isobutyl ketone; halogenated hydrocarbons such as dichloromethane;
  • Alcohols such as ethanol, isopropanol or n-butanol;
  • Ethers such as diisopropyl ether, diethoxymethane or diethylene glycol dimethyl ether;
  • Hydrocarbons such as toluene; Esters, such as ethyl acetate; aprotic solvents such as dimethylformamide, dimethylacetamide, dimethyl sulfoxide or N-ethylpyrrolidinone or
  • Phase transfer catalysts such as quaternary ammonium or phosphonium salts, for example dimethylditetradecylammonium bromide, benzyltriethylammonium chloride, Alliquat ® 336 (3-methyltrioctylammonium chloride), tetrabutylammonium hydrogen sulfate, or tetrabutylphosphonium chloride;
  • bases is understood as meaning alkali metal hydroxides, for example sodium hydroxide or potassium hydroxide, caustic soda in solid form or in the form of alkalis of different concentrations, alkali metal hydrides and alkaline earth metal hydrides, for example sodium hydride, calcium hydride, amides, for example sodium amide, alcoholates, for example sodium methoxide, potassium tert-butoxide.
  • organometallic compounds for example n-butyllithium, or amines, for example diethylisopropylamine, or mixtures of the abovementioned inorganic bases
  • halogen refers to fluorine, chlorine, bromine and iodine understood.
  • - (C-j-C / jJ-alkyl are hydrocarbon radicals such as methyl, ethyl, propyl, n-butyl or
  • Suitable acids are, for example, hydrochloric acid, sulfuric acid, nitric acid or phosphoric acid or mixtures of the acids.
  • the amount of solvent used is generally from 3 kg to 11 kg per kg of the compound of the formula II or IV, preferably from 4 kg to 6 kg.
  • the reaction time is generally between a few minutes and 24 hours, preferably 1 to 3 hours, depending on the composition of the mixture and the selected temperature range.
  • the reaction temperature is from -5 ° C to 50 ° C, preferably from 0 ° C to 30 ° C, especially 10 ° C.
  • the residual content of the starting substrate of the compound of the formula II or 2-cyano-N- (4-trifluoromethyl-phenyl) -acetamide could be determined in isolated 2-cyano-3-hydroxy-N - [(4-trifluoromethyl) -phenyl] but-2-one. enamide are reduced below a level of 0.5%.
  • the starting material for the reaction according to the invention can be prepared by processes known from the literature, for example DE 1 900947.
  • the process product is biologically active and is suitable, for example, for the treatment of rheumatoid arthritis or multiple sclerosis.
  • Advantageous in the process according to the invention are the very short reaction times, the omission of additional purification steps, the high yields and the high purity of the product produced.
  • Advantage of the method according to the invention is the substantially complete reaction to the compound of formula I or 2-cyano-3-hydroxy-N - [(4-trifluoromethyl) phenyl] but-2-enamide and a total by-product content of less than 1%.
  • Triethylamine Adjust 5 mL with H 3 P0 4 85% to pH 6.0 5
  • Test solution Dissolve 12.5 mg of the substance in acetonitrile R to 25 mL.
  • FN ' peak area of the respective by-product in the chromatogram of the test solution
  • ⁇ F sum of all peak areas in the chromatogram of the test solution except for the injection peak
  • PTC phase transfer catalyst
  • Example 9 In a 200 ml four-necked flask, 9.1 g of 2-cyano-N- (4-trifluoromethyl-phenyl) acetamide were weighed and then suspended by addition of 49 ml of methyl isobutyl ketone (slightly yellow thin suspension), which was then cooled to 10 ° C. At this temperature, 17.8 ml of 33% NaOH was added directly from the graduated cylinder. The temperature rose to 12 ° C and there was a difficult to stir kremepme suspension. This was vigorously stirred for 10 minutes. Thereafter, 9.7 ml of acetic anhydride are added dropwise at 7 to 12 ° C within 1 h and 20 min.
  • the mixture was stirred for 50 minutes and cooled to 3 to 5 ° C. Then 11.5 ml of water were added dropwise within 10 min at this temperature, the mixture had a pH of 7.1. Subsequently, 16 ml of 37% HCl were added dropwise within 1 h, so that at a constant temperature, a pH of 1.1 was reached. After further stirring for 25 minutes, the pH was still at 1.1 (cream-colored, non-homogeneous stirrable suspension, already after about 7 ml of HCl). Within the next 20 minutes, 47.5 ml of water were added dropwise, the temperature rising to 10 ° C. The pH rose to 1.7. The mixture was then stirred for 40 min.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PCT/EP2004/002311 2003-03-18 2004-03-06 Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden Ceased WO2004083165A1 (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SI200431463T SI1606246T1 (sl) 2003-03-18 2004-03-06 Postopek za pripravo 2-cian-3-hidroksi-N-(fenil)but-2-enamidov
PL04718192T PL1606246T3 (pl) 2003-03-18 2004-03-06 Sposób wytwarzania 2-cyjano-3-hydroksy-N-(fenylo)but-2-enamidów
EP04718192A EP1606246B1 (de) 2003-03-18 2004-03-06 Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden
DE502004011176T DE502004011176D1 (de) 2003-03-18 2004-03-06 Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden
HK06106890.2A HK1086818B (en) 2003-03-18 2004-03-06 Method for producing 2-cyan-3-hydroxy-n-(phenyl)but-2-ene amides
DK04718192.0T DK1606246T3 (da) 2003-03-18 2004-03-06 Fremgangsmåde til fremstilling af 2-cyan-3-hydroxy-N-(phenyl)but-2-enamider
AU2004222139A AU2004222139B2 (en) 2003-03-18 2004-03-06 Method for producing 2-cyan-3-hydroxy-N-(phenyl)but-2-ene amides
CA2519209A CA2519209C (en) 2003-03-18 2004-03-06 Method for producing 2-cyano-3-hydroxy-n(phenyl)but-2-enamides
JP2006504568A JP4546952B2 (ja) 2003-03-18 2004-03-06 2−シアノ−3−ヒドロキシ−n−(フェニル)ブタ−2−エンアミドの製法
KR1020057017413A KR101072237B1 (ko) 2003-03-18 2004-03-06 2-시아노-3-하이드록시-n-(페닐)부트-2-엔 아미드의제조방법
MXPA05009764A MXPA05009764A (es) 2003-03-18 2004-03-06 Metodo para producir 2-ciano-3-hidroxi-n-(fenil)but-2-enamidas.
AT04718192T ATE468323T1 (de) 2003-03-18 2004-03-06 Verfahren zur hertellung von 2-cyan-3-hydroxy-n- (phenyl)but-2-enamiden
IL170934A IL170934A (en) 2003-03-18 2005-09-18 Method for producing 2-cyan-3-hydroxy-n-(phenyl)but-2-ene amides

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10311763A DE10311763A1 (de) 2003-03-18 2003-03-18 Verfahren zur Herstellung von 2-Cyan-3-hydroxy-N-(phenyl)but-2-enamiden
DE10311763.6 2003-03-18

Publications (1)

Publication Number Publication Date
WO2004083165A1 true WO2004083165A1 (de) 2004-09-30

Family

ID=32945937

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2004/002311 Ceased WO2004083165A1 (de) 2003-03-18 2004-03-06 Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden

Country Status (20)

Country Link
EP (1) EP1606246B1 (https=)
JP (1) JP4546952B2 (https=)
KR (1) KR101072237B1 (https=)
CN (1) CN100361967C (https=)
AR (1) AR043624A1 (https=)
AT (1) ATE468323T1 (https=)
AU (1) AU2004222139B2 (https=)
CA (1) CA2519209C (https=)
CY (1) CY1110722T1 (https=)
DE (2) DE10311763A1 (https=)
DK (1) DK1606246T3 (https=)
ES (1) ES2346215T3 (https=)
IL (1) IL170934A (https=)
MX (1) MXPA05009764A (https=)
PL (1) PL1606246T3 (https=)
PT (1) PT1606246E (https=)
RU (1) RU2330838C2 (https=)
SI (1) SI1606246T1 (https=)
TW (1) TW200503995A (https=)
WO (1) WO2004083165A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147624A3 (en) * 2008-06-05 2010-12-09 Alembic Limited A process for preparing teriflunomide
WO2013113037A1 (en) * 2012-01-28 2013-08-01 Optmed, Inc. Improved 1, 1-disubstituted ethylene process

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104995166A (zh) * 2013-01-29 2015-10-21 Opt迈德有限公司 改进的1,1-二取代的乙烯方法
CN104693070A (zh) * 2013-12-10 2015-06-10 深圳翰宇药业股份有限公司 一种特立氟胺的合成方法
CN105272882B (zh) * 2014-07-23 2019-05-31 欣凯医药化工中间体(上海)有限公司 一种环保简便制备泰瑞米特的方法
CN116924937A (zh) * 2022-04-02 2023-10-24 江苏康缘药业股份有限公司 2-氰基-3-羟基-2-丁烯-(4-三氟甲基-苯基)酰胺制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257882A1 (en) * 1986-08-08 1988-03-02 Lilly Industries Limited N-Phenyl butenamides with pharmaceutical properties
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
US5700822A (en) * 1994-01-07 1997-12-23 The Regents Of The University Of California Treatment of platelet derived growth factor related disorders such as cancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636974A1 (de) * 1996-09-12 1998-03-19 Hoechst Ag 2-Cyano-3,5-dihydroxy-hex-2-en- carbonsäureamidderivate
WO2002034251A1 (en) * 2000-10-20 2002-05-02 Parker Hughes Institute Treatment of asthma with lfm analogues

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0257882A1 (en) * 1986-08-08 1988-03-02 Lilly Industries Limited N-Phenyl butenamides with pharmaceutical properties
US5700822A (en) * 1994-01-07 1997-12-23 The Regents Of The University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5519042A (en) * 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUTAPA GHOSH ET AL: "Three leflunomide analogs", ACTA CRYSTALLOGR. SECT. C CRYST. STRUCT. COMMUN., vol. 56, no. 10, 2000, pages 1254 - 1257, XP002959255 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009147624A3 (en) * 2008-06-05 2010-12-09 Alembic Limited A process for preparing teriflunomide
US8389757B2 (en) 2008-06-05 2013-03-05 Alembic Ltd. Process for preparing teriflunomide
WO2013113037A1 (en) * 2012-01-28 2013-08-01 Optmed, Inc. Improved 1, 1-disubstituted ethylene process
US11555011B2 (en) 2012-01-28 2023-01-17 H.B. Fuller Company 1,1-disubstituted ethylene process

Also Published As

Publication number Publication date
ES2346215T3 (es) 2010-10-13
CA2519209A1 (en) 2004-09-30
AR043624A1 (es) 2005-08-03
EP1606246A1 (de) 2005-12-21
CA2519209C (en) 2011-12-06
PL1606246T3 (pl) 2010-10-29
TW200503995A (en) 2005-02-01
DK1606246T3 (da) 2010-09-06
AU2004222139A1 (en) 2004-09-30
DE10311763A1 (de) 2004-10-07
CY1110722T1 (el) 2015-06-10
JP4546952B2 (ja) 2010-09-22
SI1606246T1 (sl) 2010-08-31
RU2005132162A (ru) 2006-02-10
JP2006520345A (ja) 2006-09-07
CN1756737A (zh) 2006-04-05
AU2004222139B2 (en) 2010-03-04
KR101072237B1 (ko) 2011-10-12
IL170934A (en) 2009-11-18
PT1606246E (pt) 2010-07-21
HK1086818A1 (zh) 2006-09-29
EP1606246B1 (de) 2010-05-19
DE502004011176D1 (de) 2010-07-01
CN100361967C (zh) 2008-01-16
ATE468323T1 (de) 2010-06-15
KR20050120647A (ko) 2005-12-22
RU2330838C2 (ru) 2008-08-10
MXPA05009764A (es) 2005-10-26

Similar Documents

Publication Publication Date Title
EP2086944A1 (de) Verfahren zur herstellung von difluormethylpyrazolylcarboxylaten
EP2285779A1 (de) Verfahren zur herstellung von arylcarboxamiden
WO1995032952A1 (en) Process for the preparation of 3-aryluracils
EP3157900B1 (de) Verfahren zur herstellung von 2-halogenacrylsäureestern
EP2847183B1 (de) Verfahren zur herstellung von triazol-verbindungen
EP3523270B1 (de) Verfahren zur herstellung von cyclopropyl-substituierten acetophenonen
DE69105850T2 (de) Verfahren zur Herstellung von Methoxyiminoacetamidverbindungen und Zwischenverbindungen.
EP1644314B1 (de) Verfahren zum herstellen von difluoracetessigs urealkylestern
WO2004083165A1 (de) Verfahren zur hertellung von 2-cyan-3-hydroxy-n-(phenyl)but-2-enamiden
WO2003037868A1 (de) Verfahren zur herstellung von 2-halogenpyridincarbonsäureamiden
WO2017080770A1 (de) Synthese von (z)-endoxifenhydrochlorid
EP0370391A2 (de) Verfahren zur Herstellung von 4,5-Dichlor-6-ethylpyrimidin
DE69518192T2 (de) Verfahren zur Herstellung von N-Alkyl-N-Pyridinyl-1H-Indol-1-Aminen
DE69417526T2 (de) Verfahren zur Herstellung von cis-1-Aminoindan-2-ol
DE69328798T2 (de) Verfahren zur Herstellung von 3-Hydroxymethyl-1-propargyl-imidazolidin-2,4-dion
DE69802176T2 (de) ein neues verfahren für die Herstellung von 3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide
EP1131298B1 (de) Verfahren zur herstellung von 1-substituierten 5-hydroxypyrazolen
EP1926717B1 (de) Verfahren zur Herstellung von 3,4-Dichlor-N-(2-cyano-phenyl)-5-isothiazolcarboxamid
EP0720980B1 (de) Verfahren zur Herstellung von Alkylcarbonsäure-4-Hydroxyaniliden
WO2001036405A1 (de) Verfahren zur herstellung von benzofuranonoximen
EP1288197A2 (de) N-unsubstituierte Amidinium-Salze
US6894184B2 (en) Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides
AT505046A1 (de) Verfahren zur herstellung von 3,4-disubstituierten phenylessigsäuren, sowie neue zwischenverbindungen
EP3548463B1 (de) Verfahren zur herstellung von 3-substituierten 2-vinylphenylsulfonaten
RU2315749C1 (ru) Способ получения 2,4,6-трихлор-3,5-динитроанилина

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004718192

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20048058365

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2519209

Country of ref document: CA

Ref document number: PA/a/2005/009764

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2273/CHENP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004222139

Country of ref document: AU

Ref document number: 2006504568

Country of ref document: JP

Ref document number: 1020057017413

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 170934

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2004222139

Country of ref document: AU

Date of ref document: 20040306

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004222139

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005132162

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004718192

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057017413

Country of ref document: KR